Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FuFei HuaZhuo TongLuo Granule for ASS-ILD
NCT07836790Not yet recruiting
- Sponsor
- Hangzhou First People's Hospital
- Start
- Oct 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Randomised, double-blind trial of FuFei HuaZhuo TongLuo Granule in antisynthetase syndrome-associated interstitial lung disease (ASyS-ILD) (2 arms), sponsored by Hangzhou First People's Hospital. Primary endpoint: Proportion of Participants Achieving Glucocorticoid Tapering to ≤7.5 mg/day at 24 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
FuFei HuaZhuo TongLuo Granule
03
Conditions
antisynthetase syndrome-associated interstitial lung disease (ASyS-ILD)
Beyond the preview
Go deeper on NCT07836790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07836790.